Fasting Blood Sugar and Serum Triglyceride as the Risk Factors of Colorectal Adenoma in Korean Population Receiving Screening Colonoscopy

Jeung Hui Pyo, Eun Sun Kim, Hoon Jai Chun, Bora Keum, Yoon Tae Jeen, Hong Sik Lee, Chang Duck Kim, Ho Sang Ryu, Young Ha Kim, Jung Eun Lee

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Institute of Digestive Disease and Nutrition, Korea University College of Medicine, Seoul 136-705, Korea
Department of Food and Nutrition, Sookmyung Women’s University, Seoul 140-742, Korea

In several previously reported studies, metabolic syndrome (MS) was found to be associated with colorectal adenomas. While the incidence of colorectal adenoma is growing in Korean population, there are only few studies that examined the association between MS and colorectal adenoma in Korea. The aim of this study was to investigate relationships between prevalence of colorectal adenoma and MS components. We conducted a cross sectional study using data from individuals who had undergone complete colonoscopy for health examinations at the Health Promotion Center of Korea University Medical Center from July 1, 2004 to July 31, 2010. A total of 7481 subjects (4459 males and 3022 females) were included; 1733 subjects with pathologically proven adenoma were assigned to the case group, and other 5748 subjects were assigned to the non-case group. All the participants underwent colonoscopy and received blood biochemical tests (fasting blood sugar [FBS], insulin, lipid profile, hemoglobin, blood urea nitrogen [BUN], creatinine). Univariate analysis showed that the prevalence of colorectal adenoma was higher in individuals with higher blood pressure, body mass index (BMI), total cholesterol (TC), triglyceride (TG), FBS and lower high-density lipoprotein cholesterol (HDL-C) levels, compared to those with low levels. Multiple logistic regression analysis revealed that high levels of BMI (OR 1.17, 95% CI 1.01-1.34, P trend = 0.01), TG (OR 1.27, 95% CI 1.07-1.51, P trend = 0.006), and FBS (OR 1.19, 95% CI 1.01-1.40, P trend = 0.05) were significantly associated with prevalence of colorectal adenoma. Subjects with high levels of BMI, TG and FBS have increased prevalence of developing colorectal adenoma in Korea.

Key Words: BMI, Colorectal adenoma, Metabolic syndrome, Triglyceride

Introduction

Colorectal cancer (CRC) is the third most common cancer and the fourth most frequent cause of cancer death worldwide [1]. However, globally both the incidence of colorectal cancer and deaths due to this cancer has been decreasing recently, probably due to improvements of the lifestyle and more effective colorectal cancer screening. In contrast, the incidence of colorectal cancer and deaths from this tumor are still increasing in Korea. According to a report from the Ministry of Health and Welfare of Korea, colorectal cancer was the second most commonly diagnosed malignancy in 2009 [2].
MS components and colon adenoma

The rapid increase in the incidence of and death from CRC is considered to be related to adoption of a western diet rich in processed meat, high-fat foods, and refined rapidly digestible carbohydrates [3].

Most CRCs develop through the adenoma–carcinoma sequence, which allows for screening and prevention of CRCs by colonoscopic examination and polypectomy [4-6]. Understanding risk factors for colorectal neoplasm can provide guidance in developing strategies targeted toward its prevention. Several risk factors for colorectal neoplasm have been proposed, including family history of CRCs and polyps, inflammatory bowel disease, cigarette smoking, lack of physical activity, and obesity [7].

Metabolic syndrome (MS) is typically characterized by glucose intolerance, obesity, hypertension, and dyslipidemia. MS and CRC share common risk factors. Clinical characteristics of MS, such as obesity, dyslipidemia, and insulin resistance, have been linked to increased risk of CRC [7-10]. Several studies suggested development of CRC through dysregulation of insulin and insulin-like growth factors (IGFs), the so-called IGF axis, as the underlying mechanism. Other mechanisms that may account for the link between adiposity and CRC risk include inflammation, altered immune response, oxidative stress, as well as disturbances in adipokines, and sex steroids [11]. However, in contrast to CRC, studies that have suggested an association between clinical manifestations of MS and colorectal adenoma have shown considerable heterogeneity [12-17]. Moreover, there are only few studies examining the association between the individual components of MS and colorectal adenoma in Korea [18]. Thus, in the present study, we focused on the association between individual components of MS and colorectal adenoma in a Korean population.

Materials and Methods

Study population

We enrolled a consecutive series of 7481 adult subjects who underwent a voluntary, complete screening colonoscopy at health care unit of Korea University Medical Center Anam Hospital from July 1, 2004 to July 31, 2010. All the participants received blood biochemical tests (fasting blood sugar (FBS), insulin, lipid profile, hemoglobin, blood urea nitrogen (BUN), creatinine). We excluded subjects whose polyps were not histologically confirmed, or those with incomplete colonoscopy or poor results, colorectal cancer, carcinoid tumor, a past history of inflammatory bowel disease, a past history of colorectal cancer, or other malignancies. A total of 7481 subjects (4459 males and 3022 females) were included and divided into either case or non-case group; 1733 subjects with pathologically confirmed colorectal adenomas, such as tubular, villous, or dysplastic adenoma were included in the case group, and 5748 subjects with normal findings or non-neoplasia, such as hyperplastic polyps or non-specific colitis were included in the non-case group. The hospital ethics committee approved this study and we performed according to Helsinki declaration.

Laboratory assessment and Measurements

Hemoglobin was obtained in all subjects by standard laboratory methods (Toshiba 200-FR, Japan). Blood was centrifuged, and plasma was analyzed for levels of BUN, creatinine, tri-glyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), glucose, C-reactive protein (CRP) (Sysmex XE-5066, USA), and insulin (Gamma-pro, Korea). Low-density lipoprotein cholesterol (LDL-C) was calculated by Friedewald formula. Friedewald formula drives LDL-C from TC, HDL-C, and TG in fasting state: \[ \text{LDL-C} = \text{TC} - \text{HDL-C} - \frac{\text{TG}}{5} \]. At the center, height and weight were measured using Inbody 4.0 (Biospace, Korea); height was measured without shoes, to the nearest 0.01 centimeter; and weight was directly measured without shoes and heavy outer garments, to the nearest 0.01 kg. The waist to hip ratio (W/H ratio) and body mass index (BMI) (kg/m²) for all patients was calculated. Blood pressure (BP) was determined twice by a nurse after a 5-min rest in a sitting position; and the average was taken as the measurement of BP.

Colonoscopy and diagnosis of colorectal adenoma

Complete colonoscopy that reached at least the cecum after bowel preparation with polyethylene glycol was performed. Colonoscopy (Evis Lucera spectrum CLV-260SL Light Source, Olympus, Japan) was performed on each subject by two experienced colonoscopists, who were blinded to the metabolic status of the subjects. The characteristics of the adenoma, including location, number, size, and pathology report were documented. The cecum, ascending colon, and transverse colon were defined as proximal colon, whereas the descending colon, sigmoid colon, and rectum were defined as distal colon. The pathological diagnosis and definition of colorectal adenoma was based on the World Health Organization classification [19]. All specimens were diagnosed with histological descriptions by pathologists.
**Definitions**

The definition of obesity was BMI ≥ 25 kg/m², as recommended by the Korean Ministry of Health and Welfare in 2006 [20]. MS was evaluated as defined by the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III). MS was diagnosed when three or more of the following criteria were met: (1) BMI ≥ 25 kg/m²; (2) TG ≥ 150 mg/dL, or on drug treatment for elevated TG; (3) HDL-C < 40 mg/dL in males and < 50 mg/dL in females, or on drug treatment for reduced HDL-C; (4) BP ≥ 130/85 mmHg, or on drug treatment for hypertension; and (5) FBS ≥ 110 mg/dL, or on drug treatment for elevated glucose.

**Statistical analysis**

We compared age, sex, anthropometric measures and biomarkers between adenoma cases and non-cases using a t-test. We used logistic regression models to examine the associations between BMI, insulin, CRP, systolic and diastolic blood pressures, TG, total, HDL-, and LDL-C, and FBS. We grouped SBP (<120, 120-130, 130-140, and >140 mmHg), DBP (<70, 70-80, 80-90, and >90 mmHg) and BMI (<18.5, 18.5-23, 23-25, and >25 kg/m²) according to diagnostic criteria. We categorized other continuous variables into quartiles. To determine a list of covariates adjusted in the multivariate models, we fitted crude or age-and sex-adjusted models and examined the statistical significance for each variable. We also performed stepwise regression and found that diastolic blood pressure (DBP), TG and total, HDL- and LDL-C were selected at a significance level of 0.1. In the multivariate models, we adjusted for age, sex, DBP, TG, TC and FBS in the multivariate models. We calculated odds ratios (ORs) and 95% confidence intervals (CIs) using the logistic regression model. All statistical analyses were performed using SAS software version 9.3 (SAS Institute Inc., Cary, NC, USA) and p values < 0.05 were considered significant.

**Results**

**General characteristics and blood parameters**

Among the case group, there were 1217 (70.23%) males and 516 (29.77%) females. Demographic characteristics and basic measurements, including age, sex, BP, BMI, hemoglobin, TC, HDL-C, TG, FBS, BUN, creatinine, insulin, and CRP are listed in Table 1. As a whole, subjects with colorectal adenomas were older (mean age 53.45 ± 9.38 vs. 49.03 ± 10.45, p < 0.001), had higher blood pressure, BMI, TC, TG, FBS, insulin, CRP, and lower HDL-C levels than those without colorectal adenomas.

**Crude and age-sex-adjusted analyses**

In crude models, we found higher prevalence of colorectal adenoma with increasing levels of SBP, BMI, TG, TC, FBS, and CRP, and lower prevalence of adenoma with increasing HDL-C. Multiple logistic regression analysis, adjusted for age and sex, revealed that high levels of BMI (OR 1.17 for quartile 4 vs. quartile 1, 95% CI 1.03-1.34, P trend = 0.005), TG (OR 1.27 for quartile 4 vs. quartile 1, 95% CI 1.08-1.49, P trend = 0.004), TC (OR 1.13 for quartile 4 vs. quartile 1, 95% CI 0.97-1.32, P trend = 0.04), and FBS (OR 1.22 for quartile 4 vs. quartile 1, 95% CI 1.03-1.43, P trend = 0.02) were associated with significantly higher prevalence of colorectal adenomas (Table 2). OR for colorectal adenoma increased from the lowest to the highest quartiles in TG in a dose-response way; compared to quartile 1, ORs (95% CIs) were 1.10 (0.99-1.37) for quartile 2, 1.16 (0.99-1.37) for quartile 3, and 1.27 (1.08-1.49) for quartile 4 (P trend = 0.004). For FBS, compared to quartile 1, ORs (95% CIs) were 1.12 (0.95-1.33) for quartile 2, 1.28 (1.09-1.51) for quartile 3, and 1.22 (1.03-1.43) for quartile 4 (P trend = 0.02). However, we found lower prevalence of colorectal adenoma with increasing levels of DBP and LDL-C.

**Multivariate analysis adjusted for age, sex, DBP, TC, TG, and FBS**

Multivariate logistic regression analysis adjusted for age, sex, DBP, TC, TG and FBS revealed that BMI, TG, and FBS, among the MS components, were significantly associated with higher prevalence of colorectal adenoma (Table 3); comparing quartile 4 to quartile 1, ORs (95% CIs) were 1.17 (1.01-1.34; P trend = 0.01) for BMI, 1.27 (1.07-1.51; P trend = 0.006) for TG, and 1.19 (1.01-1.40; P trend = 0.05) for FBS. We found lower prevalence of colorectal adenoma with increasing levels of DBP, LDL-C and insulin.

**Discussion**

Our findings support the evidence that BMI, TG and FBS, key components of MS, are associated with prevalence of colorectal adenoma in Korean adults.

Previous studies have found that MS increases the risk of colorectal adenoma by 1.3 to 2 times [13,14,17,21]. In present study, we addressed the positive relationship between...
colorectal adenoma and the components of MS. Recently, it has been shown in several studies that high BMI and TG levels were related to the development of colorectal adenoma [17,21]. Another case-control study reported that only large waist circumference was associated with the development of colorectal adenoma [13]. Consistent with previous reports, this study confirms that high BMI, TG and FBS levels are independent risk factors for colorectal adenoma among the five components of MS in a Korean population.

Although NCEP-ATP I I requires waist circumference for diagnosis of MS, we used BMI as an indicator of obesity because the cut-off points of waist circumference in Koreans differ from those currently recommended by the NCEP-ATP I I. The cut-off points of waist circumference for central obesity in Koreans are 90 cm for men and 85 cm for women [22]. Moreover, currently there is no equivalent method for the measurement of waist circumference, whereas BMI is an easy and accurate index. Waist circumference measurements show strong between-observer differences, and should, where possible, be carried out by one observer. Weight and height are the most precisely measured variables, and it is entirely appropriate that they continue to be the predominant measure of choice in

### Table 1. General characteristics of participants according to colorectal adenoma status*

|                          | Normal                  | Adenoma                   | p value  |
|--------------------------|-------------------------|----------------------------|----------|
| Age, yr                  | 49.03 ± 10.45           | 53.45 ± 9.38              | <0.001   |
| Sex, %                   |                         |                            | <0.001   |
| Men                      | 56.40                   | 70.23                      |          |
| Women                    | 43.60                   | 29.77                      |          |
| W/H ratio                | 0.89 ± 0.05             | 0.90 ± 0.04                | <0.001   |
| Height, cm               | 164.2 ± 8.61            | 165.5 ± 8.23               | <0.001   |
| Weight, kg               | 65.18 ± 11.40           | 67.26 ± 10.69              | <0.001   |
| Hemoglobin, g/dL         | 14.44 ± 1.54            | 14.76 ± 1.40               | <0.001   |
| BUN, mg/dL               | 12.72 ± 3.33            | 13.19 ± 3.44               | <0.001   |
| Creatinine, mg/dL        | 0.92 ± 0.19             | 0.95 ± 0.19                | <0.001   |
| Insulin, uIU/mL          | 8.88 ± 3.99             | 8.91 ± 5.04                | 0.85     |
| C-reactive protein, mg/dL| 1.49 ± 3.79             | 1.60 ± 4.26                | 0.36     |
| Total cholesterol, mg/dL | 187.4 ± 32.99           | 189.6 ± 33.18              | 0.01     |
| Prevalence of metabolic syndrome, %† | 14.90 | 19.03 | <0.001 |
| SBP, mmHg                | 117.1 ± 13.33           | 118.8 ± 13.75              | <0.001   |
| DBP, mmHg                | 69.98 ± 10.92           | 70.54 ± 10.43              | 0.05     |
| SBP ≥ 130 or DBP ≥ 85 mmHg, % | 23.41 | 30.13 | <0.001 |
| BMI, kg/m²               | 24.07 ± 3.05            | 24.48 ± 2.81               | <0.001   |
| BMI ≥ 25 kg/m², %        | 35.99                   | 42.57                      | <0.001   |
| HDL-C, mg/dL             | 53.52 ± 13.47           | 51.58 ± 12.70              | <0.001   |
| HDL-C < 40 mg/dL in males and HDL-C < 50 mg/dL in female, % | 23.08 | 23.08 | >0.99 |
| Triglyceride, mg/dL      | 13.11 ± 87.64           | 144.8 ± 95.36              | <0.001   |
| Triglyceride ≥ 150 mg/dL | 28.17                   | 33.66                      | <0.001   |
| FBS, mg/dL               | 95.83 ± 18.36           | 97.99 ± 16.85              | <0.001   |
| FBS ≥ 110 mg/dL, %       | 11.24                   | 14.46                      | <0.001   |

W/H ratio: waist to hip ratio, BUN: blood urea nitrogen, SBP: systolic blood pressure, DBP: diastolic blood pressure, BMI: body mass index, HDL-C: high-density lipoprotein cholesterol, FBS: fasting blood sugar.

*Values are presented as mean ± SD unless otherwise indicated; † Metabolic syndrome is diagnosed when three out of the five following: SBP ≥ 130 or DBP ≥ 85 mmHg; BMI ≥ 25 kg/m²; HDL-C < 40 mg/dL in males and HDL-C < 50 mg/dL in female; triglyceride ≥ 150 mg/dL; FBS ≥ 110 mg/dL.
### Table 2. Odds ratios (ORs) and 95% confidence intervals (CIs) for colorectal adenoma according to clinical biomarkers

| Clinical biomarkers | Categories   | P trend |
|---------------------|--------------|---------|
| SBP, mmHg           | <120 | 120-130 | 130-140 | >140 |
| Mean                | 104.1 | 120.0 | 130.0 | 143.4 |
| Crude OR (95% CI)   | 1.00 | 0.95 (0.84-1.08) | 1.38 (1.18-1.61) | 1.37 (1.13-1.65) | <0.001 |
| Age-sex adjusted OR (95% CI) | 1.00 | 0.73 (0.64-0.84) | 0.95 (0.81-1.12) | 0.85 (0.70-1.04) | 0.12 |
| DBP, mmHg           | <70 | 70-80 | 80-90 | >90 |
| Mean                | 57.2 | 70.0 | 80.0 | 92.0 |
| Crude OR (95% CI)   | 1.00 | 1.14 (1.00-1.30) | 1.08 (0.93-1.25) | 1.18 (0.94-1.48) | 0.17 |
| Age-sex adjusted OR (95% CI) | 1.00 | 0.85 (0.74-0.97) | 0.71 (0.60-0.83) | 0.75 (0.59-0.95) | <0.001 |
| BMI, kg/m²          | <18.5 | 18.5-23 | 23-25 | >25 |
| Mean                | 17.7 | 21.3 | 23.9 | 27.2 |
| Crude OR (95% CI)   | 0.59 (0.36-0.96) | 1.00 | 1.20 (1.04-1.39) | 1.41 (1.24-1.61) | <0.001 |
| Age-sex adjusted OR (95% CI) | 0.77 (0.46-1.28) | 1.00 | 0.99 (0.85-1.14) | 1.17 (1.03-1.34) | 0.005 |
| TG, mg/dL           | Quartile 1* | Quartile 2* | Quartile 3* | Quartile 4* |
| Mean                | 60.7 | 93.6 | 133.2 | 249.1 |
| Crude OR (95% CI)   | 1.00 | 1.28 (1.00-1.51) | 1.46 (1.25-1.71) | 1.62 (1.39-1.90) | <0.001 |
| Age-sex adjusted OR (95% CI) | 1.00 | 1.10 (0.99-1.37) | 1.16 (0.99-1.37) | 1.27 (1.08-1.49) | 0.004 |
| Total cholesterol, mg/dL | 147.8 | 176.2 | 196.9 | 231.2 |
| Mean                | 38.0 | 47.5 | 55.7 | 70.9 |
| Crude OR (95% CI)   | 1.00 | 0.94 (0.81-1.10) | 1.11 (0.96-1.30) | 1.21 (1.04-1.41) | 0.002 |
| Age-sex adjusted OR (95% CI) | 1.00 | 0.90 (0.77-1.06) | 1.03 (0.88-1.21) | 1.13 (0.97-1.32) | 0.04 |
| HDL-cholesterol, mg/dL | 76.9 | 98.8 | 116.0 | 146.2 |
| Mean                | 81.7 | 89.6 | 96.1 | 117.3 |
| Crude OR (95% CI)   | 1.00 | 1.23 (1.04-1.45) | 1.52 (1.30-1.78) | 1.71 (1.46-2.00) | <0.001 |
| Age-sex adjusted OR (95% CI) | 1.00 | 1.12 (0.95-1.33) | 1.28 (1.09-1.51) | 1.22 (1.03-1.43) | 0.02 |
| FBS, mg/dL          | 5.1 | 7.2 | 9.2 | 14.0 |
| Mean                | 0.2 | 0.5 | 1.0 | 4.4 |

SBP: systolic blood pressure, DBP: diastolic blood pressure, BMI: body mass index, TG: triglyceride, HDL: high-density lipoprotein, LDL: low-density lipoprotein, FBS: fasting blood sugar, CRP: C-reactive protein.

*Quartile cutoff values: TG; 77, 110, 161 mg/dL; total cholesterol; 165, 186, 208 mg/dL; HDL-cholesterol; 43, 51, 60 mg/dL; LDL-cholesterol; 89, 107, 125 mg/dL; FBS; 86, 92, 100 mg/dL; insulin, 6.3, 8.1, 10.6 uIU/mL; CRP; 0.4, 0.7, 1.4 mg/dL.
MS components and colon adenoma

Table 3. Multivariate odds ratios (ORs) and 95% confidence intervals (CIs)* for colorectal adenoma according to clinical biomarkers

| Clinical biomarkers | Categories | OR (95% CI) | P trend |
|---------------------|------------|-------------|---------|
| SBP, mmHg           | <120       | 1.00        |         |
| Mean                | 104.1      | 1.00        |         |
| OR (95% CI)         | 0.72 (0.63-0.82) | 0.91 (0.77-0.77) | 0.81 (0.66-0.99) | 0.06 |
| DBP, mmHg           | <70        | 1.00        |         |
| Mean                | 57.2       | 1.00        |         |
| OR (95% CI)         | 0.82 (0.72-0.95) | 0.68 (0.58-0.79) | 0.69 (0.55-0.88) | <0.001 |
| BMI, kg/m²          | <18.5      | 1.00        |         |
| Mean                | 17.7       | 1.00        |         |
| OR (95% CI)         | 0.79 (0.47-1.32) | 0.98 (0.85-1.14) | 1.17 (1.01-1.34) | 0.01 |
| Triglyceride, mg/dL |            |             |         |
| Mean                | 60.7       | 1.00        |         |
| OR (95% CI)         | 0.82 (0.72-0.95) | 0.68 (0.58-0.79) | 0.69 (0.55-0.88) | <0.001 |
| HDL-cholesterol, mg/dL |          |             |         |
| Mean                | 38.0       | 1.00        |         |
| OR (95% CI)         | 0.86 (0.66-0.91) | 0.94 (0.70-0.98) | 0.94 (0.80-1.12) | 0.50 |
| LDL-cholesterol, mg/dL |          |             |         |
| Mean                | 76.9       | 1.00        |         |
| OR (95% CI)         | 0.82 (0.66-0.91) | 0.94 (0.70-0.98) | 0.94 (0.80-1.12) | 0.50 |
| FBS, mg/dL          |            |             |         |
| Mean                | 81.7       | 1.00        |         |
| OR (95% CI)         | 0.82 (0.66-0.91) | 0.94 (0.70-0.98) | 0.94 (0.80-1.12) | 0.50 |
| Insulin, uIU/mL     |            |             |         |
| Mean                | 5.1        | 1.00        |         |
| OR (95% CI)         | 0.82 (0.66-0.91) | 0.94 (0.70-0.98) | 0.94 (0.80-1.12) | 0.50 |
| C-reactive protein, mg/dL |       |             |         |
| Mean                | 0.2        | 1.00        |         |
| OR (95% CI)         | 0.82 (0.66-0.91) | 0.94 (0.80-1.12) | 0.94 (0.80-1.12) | 0.50 |

SBP: systolic blood pressure, DBP: diastolic blood pressure, BMI: body mass index, HDL: high-density lipoprotein, LDL: low-density lipoprotein, FBS: fasting blood sugar.

*Adjusted for age (continuous), sex (male and female), DBP (<70, 70-80, 80-90, and >90), total cholesterol (quartiles), triglyceride (quartiles), and FBS (quartiles). DBP, total cholesterol, triglyceride and FBS were not adjusted when these biomarkers were examined as the main exposures.

The vast majority of nutritional anthropometric studies [23]. Therefore, most medical institutions in Korea use BMI as an indicator of obesity, defined by The Korean Ministry of Health and Welfare as BMI ≥ 25 kg/m² [20]. BMI reflects total body fatness, which is associated with insulin resistance and higher level of circulating IGF-1.

The possible mechanisms by which colorectal neoplasms arise in subjects with MS comprise inflammation, insulin resistance and oxidative stress [24]. Adipose tissue is now recognized as an endocrine organ rather than a simple fat storage site, and a wide range of inflammatory cytokines is released from adipose tissue, including CRP, tumor necrosis factor-α...
and interleukin-6 [25,26]. Adipose tissue can produce and release the inflammatory cytokines that are potentially procarcinogenic. The association of colorectal adenoma and the inflammatory cytokines has been postulated [27-29]. A previous study has suggested that elevated CRP, a widely used marker of inflammation, is associated with increased risk of colorectal neoplasia in men [30]. In the present study we examined the association between CRP level and colorectal adenoma. However the logistic analysis in this study did not reveal any definite relation between CRP and colorectal adenoma. 

Colorectal polyps are common in Western countries; they are found in >30% of autopsies performed in people aged >60 yr [31]. There have been many reports on risk factors of colorectal adenomas in Western countries. Several studies found the association of BMI with increased risk of colorectal adenomas [32,33]. Among the lipid profile, a higher level of serum TG was associated with an increased risk of adenomatous polyps [34]. On the other hand, association of serum cholesterol with colorectal adenoma is still controversial [34,35]. Insulin resistance and diabetes mellitus have been associated with an increased risk of colorectal adenomas in numerous studies [36]. These results are consistent with our study. 

There were several limitations to the present study. First, the information on cigarette smoking, alcohol drinking and physical activity was not reported. Lifestyle factors also have been shown to be associated with the incidence of colorectal adenoma [33,37-39]. Second, information on detailed personal medical histories, including hypertension, diabetes mellitus, hyperlipidemia, and current medication was not reported. The possibility of reverse causation due to changes in lifestyle among those with these diseases may partly explain our findings of inverse associations for DBP, LDL-C, and insulin. Third, family history of CRC, which could be a strong risk factor for colorectal cancer, was not included. Finally, the study population was a single center cross sectional study and therefore the results of our study may not infer temporal relationship and may not be generalizable to whole Korean adult population.

Conclusion

This study shows that among the components of MS, high BMI, TG and FBS levels are positively associated with colorectal adenoma in Korean population. Individuals with high BMI, TG, or FBS may be advised to have colonoscopy to prevent CRC. MS should be considered as an important risk factor for colorectal adenoma, especially when high BMI, TG or FBS is present.

Acknowledgements

This work was provided the Korea Healthcare Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A111182) and supported by grant from Korea University.

References

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Jung KW, Park S, Kong HJ, Won YJ, Lee JY, Seo HG, Lee JS. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2009. Cancer Res Treat 2012;44:11-24.
3. Cho E, Smith-Warner SA, Ritz J, van den Brandt PA, Colditz GA, Folsom AR, Feuer E, Willett WC, Wolk A, Hunter DJ. Alcohol intake and colorectal cancer: a pooled analysis of 8 cohort studies. Ann Intern Med 2004;140:800-13.
4. Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med 2000;343:162-8.
5. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-32.
6. Winawer SJ, Zauber AG, Ho MN, O'Brien MJ, Gottlieb LS, Sternberg SS, Waye JD, Schapiro M, Bond JH, Panish JF, Ackroyd F, Shiue M, Kurtz RC, Hornsby-Lewis L, Erdes H, Stewart ET; the National Polyp Study Workgroup. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993;329:1977-81.
7. Chiu HM, Lin JT, Shun CT, Liang JT, Lee YC, Huang SP, Wu MS. Association of metabolic syndrome with proximal and synchronous colorectal neoplasms. Clin Gastroenterol Hepatol 2007;5:221-8; quiz 141.
8. Ahmed RL, Schmitz KH, Anderson KE, Rosamond WD, Folsom AR. The metabolic syndrome and risk of incident colorectal cancer. Cancer 2006;107:28-36.
9. Limburg PJ, Anderson KE, Johnson TW, Jacobs DR Jr, Lazovich D, Hong CP, Nicodemus KK, Folsom AR. Diabetes mellitus and subsite-specific colorectal cancer risks in the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev 2005;14:133-7.
10. Murphy TK, Calle EE, Rodriguez C, Kahn HS, Thun MJ. Body mass index and colon cancer mortality in a large prospective study. Am J Epidemiol 2000;152:847-54.
11. Gunter MJ, Leitzmann MF. Obesity and colorectal cancer: epidemiology, mechanisms and candidate genes. J Nutr Biochem 2006;17:145-56.
12. Bowers K, Albanes D, Limburg P, Pietinen P, Taylor PR, Virtamo J, Stolzenberg-Solomon R. A prospective study of anthropometric and clinical measurements associated with insulin resistance syndrome and colorectal cancer in male smokers. Am J Epidemiol 2006;164:652-64.
13. Kim JH, Lim YJ, Kim YH, Sung IK, Shim SG, Oh SO, Park SS, Yang S, Son HJ, Rhee PL, Kim JJ, Rhee JC, Choi YH. Is metabolic syndrome a risk factor for colorectal adenoma? Cancer Epidemiol Biomarkers Prev 2007;16:1543-6.

14. Morita T, Tabata S, Mineshita M, Mizoue T, Moore MA, Kono S. The metabolic syndrome is associated with increased risk of colorectal adenoma development: the Self-Defense Forces health study. Asian Pac J Cancer Prev 2005;6:485-9.

15. Nam SY, Kim BC, Han KS, Ryu KH, Park BJ, Kim HB, Nam BH. Abdominal visceral adipose tissue predicts risk of colorectal adenoma in both sexes. Clin Gastroenterol Hepatol 2010;8:443-50.e1-2.

16. Pelucchi C, Negri E, Talamini R, Levi F, Giacosa A, Crispo A, Bidoli E, Montiella M, Franceschi S, La Vecchia C. Metabolic syndrome is associated with colorectal cancer in men. Eur J Cancer 2010;46:1866-72.

17. Wang YY, Lin SY, Lei WA, Liu PH, Sheu WH. Association between adenomas of rectosigmoid colon and metabolic syndrome features in a Chinese population. J Gastroenterol Hepatol 2005;20:1410-5.

18. Kim MC, Kim CS, Chung TH, Park HO, Yoo CI. Metabolic syndrome, lifestyle risk factors, and distal colon adenoma: a retrospective cohort study. World J Gastroenterol 2011;17:4031-7.

19. Hamilton SR, Aaltoenen LA, editors. World Health Organization classifications of tumors. Pathology and genetics of tumours of the digestive system. Lyon: IARC Press; 2000.

20. Chen J, Giovannucci E, Kelsey K, Rimm EB, Stampfer MJ, Colditz GA, Spiegelman D, Willett WC, Hunter DJ. A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res 1996;56:4862-7.

21. Lee GE, Park HS, Yun KE, Jun SH, Kim HK, Cho SJ, Kim JH. Association between BMI and metabolic syndrome and adenomatous colorectal polyps in Korean men. Obesity (Silver Spring) 2008;16:1434-9.

22. Lee SY, Park HS, Kim DJ, Han JH, Kim SM, Cho GJ, Kim DY, Kwon HS, Kim SR, Lee CB, Oh SJ, Park CY, Yoo HJ. Appropriate waist circumference cutoff points for central obesity in Korean adults. Diabetes Res Clin Pract 2007;75:72-80.

23. Ulijaszek SJ, Kerr DA. Anthropometric measurement error and the assessment of nutritional status. Br J Nutr 1999;82:165-77.

24. Cowey S, Hardy RW. The metabolic syndrome: A high-risk state for cancer? Am J Pathol 2006;169:1505-22.

25. Trayhurn P, Beattie JH. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 2001;60:329-38.

26. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004;92:347-55.

27. Gunter MJ, Canzian F, Landi S, Chanock SJ, Sinha R, Rothman N. Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol Biomarkers Prev 2006;15:1126-31.

28. Kim S, Keku TO, Martin C, Galanko J, Woosley JT, Schroeder JC, Satia JA, Halabi S, Sandler RS. Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res 2008;68:323-8.

29. Trevisan M, Liu J, Muti P, Misiangia G, Menotti A, Fucci F. Risk Factors and Life Expectancy Research Group. Markers of insulin resistance and colorectal cancer mortality. Cancer Epidemiol Biomarkers Prev 2001;10:937-41.

30. Chiu HM, Lin JT, Chen TH, Lee YC, Chiu YH, Liang JT, Shun CT, Wu MS. Elevation of C-reactive protein level is associated with synchronous and advanced colorectal neoplasm in men. Am J Gastroenterol 2008;103:2317-25.

31. Williams AR, Balasooriya BA, Day DW. Polyps and cancer of the large bowel: a necropsy study in Liverpool. Gut 1982;23:835-42.

32. Boustou-Ruaud MC, Senesse P, Méance S, Belghiti C, Faivre J. Energy intake, body mass index, physical activity, and the colorectal adenoma-carcinoma sequence. Nutr Cancer 2001;39:50-7.

33. Giovannucci E, Colditz GA, Stampfer MJ, Willett WC. Physical activity, obesity, and risk of colorectal adenoma in women (United States). Cancer Causes Control 1996;7:253-63.

34. Bird CL, Ingles SA, Frankl HD, Lee ER, Longnecker MP, Haile RW. Serum lipids and adenomas of the left colon and rectum. Cancer Epidemiol Biomarkers Prev 1996;5:607-12.

35. Jacobs D, Blackburn H, Higgins M, Reed D, Iso H, McMillan G, Neaton J, Nelson J, Potter J, Rifkind B. Report of the Conference on Low Blood Cholesterol: Mortality Associations. Circulation 1992;86:1046-60.

36. Kominou D, Ayonote A, Richie JP Jr, Rigas B. Prevalence and risk of colorectal neoplasia in consumers of alcohol in a screening population. Am J Epidemiol 1994;140:835-41.

37. Son HJ, Rhee PL, Kim JJ, Rhee JC, Choi YH. Is metabolic syndrome a risk factor for colorectal cancer in Korean men. Ann Intern Med 1995;122:327-34.

38. Anderson JC, Alperrn Z, Sethi G, Messina CR, Martin C, Hubbard PM, Grimson R, Ellis PF, Shaw RD. Prevalence and risk of colorectal neoplasia in consumers of alcohol in a screening population. Am J Gastroenterol 2005;100:2049-55.

39. Giovannucci E, Ascherio A, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med 1995;122:327-34.